HOME >> MEDICINE >> NEWS
Premature use of stem cell therapy could put patients at risk

The premature use of stem cell therapy could put many patients at risk of viral or prion diseases unless appropriate safety systems are in place, warn experts in this week's BMJ.

The use of human embryonic stem cells has been hailed as the next major step in the battle against serious degenerative disorders, such as diabetes and Parkinson's disease. But is this just hype, and how much hope should patients invest in this technology? These are some of the issues that will be discussed at a public debate in London next week.

The lessons of premature application of gene therapy, the devastation caused by HIV transmission to people with haemophilia, and the crisis caused by bovine spongiform encephalopathy (BSE) should all be learning opportunities, say the authors.

Expansion of stem cell cultures could allow a single stem cell line to be used for many hundreds, if not thousands of patients, exponentially amplifying the potential risk of disease transmission from a single infected donor.

Change is on the way, however. By April 2006, all laboratories for in vitro fertilisation and laboratories for producing cell lines with therapeutic intent will have to comply with the EU Directive on tissues and cells. This will cover selection of donors, testing, and procurement of the starting material for cell lines, tracking cells from donor to recipient, and reporting of adverse events.

The authors suggest a novel alternative approach whereby the expanded stem cell lines themselves could be tested for a variety of pathogens before they are released. This would provide an additional safety step and provide an alternative in the armamentarium for testing these important donations for transplantation.

The drive to be the first to produce cell lines for therapy without appropriate controls could compromise safety for recipients and could lead this technology into the realms of quackery, say the authors. Such fears are already being realis
'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ-British Medical Journal
19-May-2005


Page: 1 2

Related medicine news :

1. Premature or low birthweight babies at significantly increased risk of hyperactivity disorder
2. Premature baby ventilation trial cleared of causing long-term harm to participants
3. Premature babies and SIDS: Doctors should make special effort to talk to parents About Risk
4. Chemotherapy with bevacizumab increases risk of blood clots in arteries
5. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
6. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
7. Hormone therapy offers new hope for ovarian cancer patients
8. Borderline personality disorder shows improvements with intensive psychotherapy
9. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
10. Chemotherapy may enhance the effectiveness of brain tumor vaccines
11. Brain-boosting pill alleviates post-chemotherapy fogginess

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Premature use stem cell therapy could put patients risk

(Date:2/28/2015)... Ohio (PRWEB) February 28, 2015 ... Motivational? Supportive? Strategic? , There are all kinds ... strengths. To raise awareness of the advantages and ... firm PeopleKeys is launching a new product this ... clients better understand the connection between personality type, ...
(Date:2/28/2015)... The noted Friedman Dental Group of ... officially relaunched their website. The new version of the ... a new section about their team members. Potential and ... biographies of each Friedman Dental Group team member including ... designed to provide our patients with the opportunity to ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Developers of ... of a new overlay plugin for Final Cut Pro X ... , “FCPX Overlay Chromatic gives users total control over 6k ... Austin, CEO of Pixel Film Studios. “FCPX Overlay Chromatic was ... easy to use interface.” , FCPX Overlay Chromatic Grunge 6K ...
(Date:2/28/2015)... Powermod ” was featured on NewsWatch as part of its ... and coolest technology products and services available to consumers. Scott ... conducted the review and shared with viewers how they provide ... a low battery and no way to charge a phone ... daily basis. Even when a person does have a charger, ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a ... new security reader named Guardian 2. The correct ... new biometric scanner that significantly increases the complexity ... new biometric scanner provides fast and easy access ... narcotics lockers with Vanguard technology tracks ...
Breaking Medicine News(10 mins):Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
(Date:2/27/2015)... SOUTH PLAINFIELD, N.J., Feb. 27, 2015  PTC Therapeutics, ... corporate update and reported financial results for the fourth ... "2014 was a transformative year for PTC. ... on delivering and developing RNA-targeted therapies in the rare ... Officer, PTC Therapeutics, Inc. "We are proud to bring ...
(Date:2/27/2015)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today announced that it will ... March 10, 2015. Rob Kill , President and ... will present at 4:00 p.m. Pacific Time and meet ... the Ritz Carlton in Laguna Niguel, CA. ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Uroplasty to Participate in the 27th Annual ROTH Conference 2
Cached News: